News Detail

Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)

05 Jun 2011

by:

Read the article

|